Skip to main content

Advertisement

SpringerLink
Log in

Cardiovascular issues in rheumatic diseases

  • Perspectives in Rheumatology
  • Published:
Clinical Rheumatology Aims and scope Submit manuscript

Abstract

Cardiovascular disease is a major cause of morbidity and mortality in rheumatic diseases, particularly rheumatoid arthritis and systemic lupus erythematosus. Timely detection and monitoring of cardiovascular affections by advanced visualization techniques may improve outcomes across most rheumatic diseases. Although high-grade inflammation and (auto)immune pathways are well known for their negative effects on the heart and vasculature, cardiovascular risk estimation remains one of the unresolved critical issues in rheumatic diseases. The issue is complicated further in view of the latest reports on enhanced atherogenesis in the setting of fibromyalgia and osteoarthritis, where inflammation is seemingly not a major pathogenic factor. The intensity of systemic inflammation has been associated with major vascular events in some large cohort studies of inflammatory rheumatic diseases. Experts advocate for tight control of systemic inflammation and modifiable cardiovascular risk factors for reducing the overall risk of vascular events. Increasing patients’ and specialists’ knowledge and skills in cardiovascular monitoring and prevention is warranted to solve some of the cardiovascular issues in rheumatic diseases.

Key Points

• Cardiovascular issues are prevalent across all age groups of patients with rheumatic diseases.

• Large cohort studies suggest that the intensity of systemic inflammation is a powerful predictor of vascular events in rheumatic diseases.

• Reliable and widely tested tools for predicting vascular events in inflammatory rheumatic diseases are currently unavailable.

• Empowering patients with rheumatic diseases and first-contact specialists with knowledge and skills to monitor and reduce cardiovascular risk factors’ effects is a promising strategy.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Nurmohamed MT, Heslinga M, Kitas GD (2015) Cardiovascular comorbidity in rheumatic diseases. Nat Rev Rheumatol 11(12):693–704. https://doi.org/10.1038/nrrheum.2015.112

    Article  CAS  PubMed  Google Scholar 

  2. Shah M, Shinjo SK, Day J, Gupta L (2023) Cardiovascular manifestations in idiopathic inflammatory myopathies. Clin Rheumatol Online ahead of print. https://doi.org/10.1007/s10067-023-06599-4

  3. Thomas KN, Aggarwal A (2023) Childhood rheumatic diseases: bites not only the joint, but also the heart. Clin Rheumatol Online ahead of print. https://doi.org/10.1007/s10067-023-06621-9

  4. Barsalou J, Bradley TJ, Silverman ED (2013) Cardiovascular risk in pediatric-onset rheumatological diseases. Arthritis Res Ther 15(3):212. https://doi.org/10.1186/ar4212

    Article  PubMed  PubMed Central  Google Scholar 

  5. Del Giudice E, Dilillo A, Tromba L et al (2018) Aortic, carotid intima-media thickness and flow-mediated dilation as markers of early atherosclerosis in a cohort of pediatric patients with rheumatic diseases. Clin Rheumatol 37(6):1675–1682. https://doi.org/10.1007/s10067-017-3705-7

    Article  PubMed  Google Scholar 

  6. Held M, Sestan M, Jelusic M (2023) Obesity as a comorbidity in children and adolescents with autoimmune rheumatic diseases. Rheumatol Int 43(2):209–219. https://doi.org/10.1007/s00296-022-05238-6

    Article  PubMed  Google Scholar 

  7. Gezer HH, Acer Kasman S, Duruöz MT (2022) Autonomic dysfunction and cardiovascular risk in psoriatic arthritis. Clin Rheumatol Online ahead of print. https://doi.org/10.1007/s10067-022-06484-6

  8. Mason JC, Libby P (2015) Cardiovascular disease in patients with chronic inflammation: mechanisms underlying premature cardiovascular events in rheumatologic conditions. Eur Heart J 36(8):482–49c. https://doi.org/10.1093/eurheartj/ehu403

    Article  PubMed  Google Scholar 

  9. Nikiphorou E, de Lusignan S, Mallen CD et al (2020) Cardiovascular risk factors and outcomes in early rheumatoid arthritis: a population-based study. Heart 106(20):1566–1572. https://doi.org/10.1136/heartjnl-2019-316193

    Article  CAS  PubMed  Google Scholar 

  10. del Rincón I, Battafarano DF, Restrepo JF, Erikson JM, Escalante A (2014) Glucocorticoid dose thresholds associated with all-cause and cardiovascular mortality in rheumatoid arthritis. Arthritis Rheumatol 66(2):264–272. https://doi.org/10.1002/art.38210

    Article  CAS  PubMed  Google Scholar 

  11. Nicolau J, Lequerré T, Bacquet H, Vittecoq O (2017) Rheumatoid arthritis, insulin resistance, and diabetes. Joint Bone Spine 84(4):411–416. https://doi.org/10.1016/j.jbspin.2016.09.001

    Article  CAS  PubMed  Google Scholar 

  12. Ruscitti P, Cipriani P, Masedu F et al (2017) Increased cardiovascular events and subclinical atherosclerosis in rheumatoid arthritis patients: 1 year prospective single centre study. PLoS One 12(1):e0170108. https://doi.org/10.1371/journal.pone.0170108

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  13. Lertratanakul A, Wu P, Dyer AR et al (2014) Risk factors in the progression of subclinical atherosclerosis in women with systemic lupus erythematosus. Arthritis Care Res (Hoboken) 66(8):1177–1185. https://doi.org/10.1002/acr.22271

    Article  CAS  PubMed  Google Scholar 

  14. Frerix M, Stegbauer J, Kreuter A, Weiner SM (2014) Atherosclerotic plaques occur in absence of intima-media thickening in both systemic sclerosis and systemic lupus erythematosus: a duplexsonography study of carotid and femoral arteries and follow-up for cardiovascular events. Arthritis Res Ther 16(1):R54. https://doi.org/10.1186/ar4489

    Article  PubMed  PubMed Central  Google Scholar 

  15. Rueda-Gotor J, Ferraz-Amaro I, Genre F et al (2022) Factors associated with atherosclerosis in radiographic and non-radiographic axial spondyloarthritis. A multicenter study on 838 patients. Semin Arthritis Rheum 55:152037. https://doi.org/10.1016/j.semarthrit.2022.152037

    Article  CAS  PubMed  Google Scholar 

  16. Rojas-Giménez M, López-Medina C, Ladehesa-Pineda ML et al (2022) Subclinical atherosclerosis measure by carotid ultrasound and inflammatory activity in patients with rheumatoid arthritis and spondylarthritis. J Clin Med 11(3):662. https://doi.org/10.3390/jcm11030662

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  17. Lampa J (2019) Pain without inflammation in rheumatic diseases. Best Pract Res Clin Rheumatol 33(3):101439. https://doi.org/10.1016/j.berh.2019.101439

    Article  PubMed  Google Scholar 

  18. Haviland MG, Banta JE, Przekop P (2011) Fibromyalgia: prevalence, course, and co-morbidities in hospitalized patients in the United States, 1999-2007. Clin Exp Rheumatol 29(6 Suppl 69):S79–S87

    CAS  PubMed  Google Scholar 

  19. Gunturk EE, Ekiz T, Akkaya H (2019) Evaluation of carotid-femoral pulse wave velocity, aortic stiffness index, and aortic distensibility in patients with fibromyalgia. Clin Rheumatol 38(6):1731–1735. https://doi.org/10.1007/s10067-019-04429-0

    Article  PubMed  Google Scholar 

  20. Kim Y, Kim GT, Kang J (2021) Carotid arterial stiffness and cardiometabolic profiles in women with fibromyalgia. Biomedicines 9(12):1786. https://doi.org/10.3390/biomedicines9121786

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  21. Kocyigit BF, Akyol A (2023) Coexistence of fibromyalgia syndrome and inflammatory rheumatic diseases, and autonomic cardiovascular system involvement in fibromyalgia syndrome. Clin Rheumatol 42(3):645–652. https://doi.org/10.1007/s10067-022-06385-8

    Article  PubMed  Google Scholar 

  22. Hoeven TA, Kavousi M, Clockaerts S et al (2013) Association of atherosclerosis with presence and progression of osteoarthritis: the Rotterdam study. Ann Rheum Dis 72(5):646–651. https://doi.org/10.1136/annrheumdis-2011-201178

    Article  PubMed  Google Scholar 

  23. Chung WS, Lin HH, Ho FM, Lai CL, Chao CL (2016) Risks of acute coronary syndrome in patients with osteoarthritis: a nationwide population-based cohort study. Clin Rheumatol 35(11):2807–2813. https://doi.org/10.1007/s10067-016-3391-x

    Article  PubMed  Google Scholar 

  24. Ha SJ, Park SJ, Lee B, Moon H, Kim BY (2023) Clinical outcomes of patients with rheumatoid arthritis who underwent percutaneous coronary intervention: a Korean nationwide cohort study. PLoS One 18(2):e0281067. https://doi.org/10.1371/journal.pone.0281067

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  25. Solomon DH, Reed GW, Kremer JM (2015) Disease activity in rheumatoid arthritis and the risk of cardiovascular events. Arthritis Rheumatol 67(6):1449–1455. https://doi.org/10.1002/art.39098

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  26. Lauper K, Courvoisier DS, Chevallier P, Finckh A, Gabay C (2018) Incidence and prevalence of major adverse cardiovascular events in rheumatoid arthritis, psoriatic arthritis, and axial spondyloarthritis. Arthritis Care Res (Hoboken) 70(12):1756–1763. https://doi.org/10.1002/acr.23567

    Article  PubMed  Google Scholar 

  27. Chou CH, Lin CL, Chang SN, Lin MC, Kao CH, Huang YJ (2014) A nationwide population-based retrospective cohort study: increased risk of acute myocardial infarction in systemic lupus erythematous patients. Int J Cardiol 174(3):751–753. https://doi.org/10.1016/j.ijcard.2014.04.086

    Article  PubMed  Google Scholar 

  28. Shams-Eldin AN, Yafasova A, Faurschou M et al (2022) Long-term risk of adverse cardiovascular outcomes associated with cutaneous lupus erythematosus: a nationwide cohort study. Clin Rheumatol 41(11):3525–3536. https://doi.org/10.1007/s10067-022-06302-z

    Article  PubMed  Google Scholar 

  29. Tyndall AJ, Bannert B, Vonk M et al (2010) Causes and risk factors for death in systemic sclerosis: a study from the EULAR Scleroderma Trials and Research (EUSTAR) database. Ann Rheum Dis 69(10):1809–1815. https://doi.org/10.1136/ard.2009.114264

    Article  PubMed  Google Scholar 

  30. Conrad N, Verbeke G, Molenberghs G et al (2022) Autoimmune diseases and cardiovascular risk: a population-based study on 19 autoimmune diseases and 12 cardiovascular diseases in 22 million individuals in the UK. Lancet 400(10354):733–743. https://doi.org/10.1016/S0140-6736(22)01349-6

    Article  PubMed  Google Scholar 

  31. Symmons DP, Gabriel SE (2011) Epidemiology of CVD in rheumatic disease, with a focus on RA and SLE. Nat Rev Rheumatol 7(7):399–408. https://doi.org/10.1038/nrrheum.2011.75

    Article  PubMed  Google Scholar 

  32. Agca R, Heslinga SC, Rollefstad S et al (2017) EULAR recommendations for cardiovascular disease risk management in patients with rheumatoid arthritis and other forms of inflammatory joint disorders: 2015/2016 update. Ann Rheum Dis 76(1):17–28. https://doi.org/10.1136/annrheumdis-2016-209775

    Article  CAS  PubMed  Google Scholar 

  33. Galarza-Delgado DA, Azpiri-Lopez JR, Colunga-Pedraza IJ et al (2017) Assessment of six cardiovascular risk calculators in Mexican mestizo patients with rheumatoid arthritis according to the EULAR 2015/2016 recommendations for cardiovascular risk management. Clin Rheumatol 36(6):1387–1393. https://doi.org/10.1007/s10067-017-3551-7

    Article  PubMed  Google Scholar 

  34. Crowson CS, Gabriel SE, Semb AG et al (2017) Rheumatoid arthritis-specific cardiovascular risk scores are not superior to general risk scores: a validation analysis of patients from seven countries. Rheumatology (Oxford) 56(7):1102–1110. https://doi.org/10.1093/rheumatology/kex038

    Article  CAS  PubMed  Google Scholar 

  35. Semb AG, Ikdahl E, Wibetoe G, Crowson C, Rollefstad S (2020) Atherosclerotic cardiovascular disease prevention in rheumatoid arthritis. Nat Rev Rheumatol 16(7):361–379. https://doi.org/10.1038/s41584-020-0428-y

    Article  PubMed  Google Scholar 

  36. Hansildaar R, Vedder D, Baniaamam M, Tausche AK, Gerritsen M, Nurmohamed MT (2021) Cardiovascular risk in inflammatory arthritis: rheumatoid arthritis and gout. Lancet Rheumatol 3(1):e58–e70. https://doi.org/10.1016/S2665-9913(20)30221-6

    Article  CAS  PubMed  Google Scholar 

  37. Papamichail GV, Markatseli TE, Georgiadis AN et al (2022) The effects of biologic agents on cardiovascular risk factors and atherosclerosis in rheumatoid arthritis patients: a prospective observational study. Heart Vessels 37(12):2128–2136. https://doi.org/10.1007/s00380-022-02114-y

    Article  CAS  PubMed  Google Scholar 

  38. Castañeda S, Vicente-Rabaneda EF, García-Castañeda N, Prieto-Peña D, Dessein PH, González-Gay MA (2020) Unmet needs in the management of cardiovascular risk in inflammatory joint diseases. Expert Rev Clin Immunol 16(1):23–36. https://doi.org/10.1080/1744666X.2019.1699058

    Article  PubMed  Google Scholar 

  39. Strehl C, Bijlsma JW, de Wit M et al (2016) Defining conditions where long-term glucocorticoid treatment has an acceptably low level of harm to facilitate implementation of existing recommendations: viewpoints from an EULAR task force. Ann Rheum Dis 75(6):952–957. https://doi.org/10.1136/annrheumdis-2015-208916

    Article  CAS  PubMed  Google Scholar 

  40. Ruiz-Irastorza G, Danza A, Khamashta M (2012) Glucocorticoid use and abuse in SLE. Rheumatology (Oxford) 51(7):1145–1153. https://doi.org/10.1093/rheumatology/ker410

    Article  CAS  PubMed  Google Scholar 

  41. Schrezenmeier E, Dörner T (2020) Mechanisms of action of hydroxychloroquine and chloroquine: implications for rheumatology. Nat Rev Rheumatol 16(3):155–166. https://doi.org/10.1038/s41584-020-0372-x

    Article  CAS  PubMed  Google Scholar 

  42. Misra DP, Gasparyan AY, Zimba O (2020) Benefits and adverse effects of hydroxychloroquine, methotrexate and colchicine: searching for repurposable drug candidates. Rheumatol Int 40(11):1741–1751. https://doi.org/10.1007/s00296-020-04694-2

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  43. Ferguson LD, Sattar N, McInnes IB (2021) Managing cardiovascular risk in patients with rheumatic disease. Med Clin North Am 105(2):247–262. https://doi.org/10.1016/j.mcna.2020.09.010

    Article  PubMed  Google Scholar 

  44. Bodur H (2022) Cardiovascular comorbidities in spondyloarthritis. Clin Rheumatol. https://doi.org/10.1007/s10067-022-06473-9 Online ahead of print

  45. Patel P, Rosen CF, Chandran V, Ye YJ, Gladman DD (2018) Addressing comorbidities in psoriatic disease. Rheumatol Int 38(2):219–227. https://doi.org/10.1007/s00296-017-3895-y

    Article  PubMed  Google Scholar 

  46. Banerjee S, George MD, Singh S et al (2020) (2020) Patient perception of cardiovascular risk in rheumatoid arthritis. ACR Open Rheumatol 2(5):255–260. https://doi.org/10.1002/acr2.11136

    Article  PubMed  PubMed Central  Google Scholar 

  47. Ladak K, Hashim J, Clifford-Rashotte M, Tandon V, Matsos M, Patel A (2018) Cardiovascular risk management in rheumatoid arthritis: a large gap to close. Musculoskelet Care 16(1):152–157. https://doi.org/10.1002/msc.1196

    Article  Google Scholar 

  48. Pak S (2020) Primary care providers’ awareness, knowledge, and practice with regard to cardiovascular risk in patients with rheumatoid arthritis: PCPs’ awareness, knowledge, and practice with regard to CV risks in patients with RA. Clin Rheumatol 39(3):755–760. https://doi.org/10.1007/s10067-019-04901-x

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Clinical Rheumatology and Immunology, University Hospital in Krakow, Macieja Jakubowskiego 2, 30-688, Krakow, Poland

    Olena Zimba

  2. National Institute of Geriatrics, Rheumatology and Rehabilitation, Warsaw, Poland

    Olena Zimba

  3. Department of Internal Medicine N2, Danylo Halytsky Lviv National Medical University, Lviv, Ukraine

    Olena Zimba

  4. Departments of Rheumatology and Research and Development, Dudley Group NHS Foundation Trust (Teaching Trust of the University of Birmingham, UK), Russells Hall Hospital, Dudley, UK

    Armen Yuri Gasparyan

Authors
  1. Olena Zimba
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Armen Yuri Gasparyan
    View author publications

    You can also search for this author in PubMed Google Scholar

Contributions

Both authors have substantially contributed to the writing and revision of this manuscript. They read and approve the final version of the manuscript.

Corresponding author

Correspondence to Olena Zimba.

Ethics declarations

Disclosures

None.

Additional information

Publisher’s note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Zimba, O., Gasparyan, A.Y. Cardiovascular issues in rheumatic diseases. Clin Rheumatol 42, 2535–2539 (2023). https://doi.org/10.1007/s10067-023-06656-y

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10067-023-06656-y

Keywords

Search

Navigation